Nikang Therapeutics, Inc.
Clinical trials sponsored by Nikang Therapeutics, Inc., explained in plain language.
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC